share_log

ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" From Brokerages

ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" From Brokerages

ChemoCentryx，Inc.(納斯達克代碼：CCXI)獲得券商一致給予的“持有”評級
Defense World ·  2022/09/14 02:42

ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) has earned a consensus rating of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $62.43.

據市場評級公司報道，ChemoCentryx，Inc.(納斯達克代碼：CCXI-GET Rating)已獲得目前涵蓋該股的九家評級公司的共識評級為“持有”。六位分析師對該股的評級為持有，兩位分析師給出了買入評級，一位分析師對該公司給予了強烈的買入評級。去年更新了該股覆蓋範圍的經紀商的平均12個月目標價為62.43美元。

Several equities analysts have recently issued reports on CCXI shares. StockNews.com raised shares of ChemoCentryx from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. HC Wainwright cut shares of ChemoCentryx from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $101.00 to $52.00 in a research report on Friday, August 5th. Canaccord Genuity Group initiated coverage on shares of ChemoCentryx in a research report on Thursday, August 4th. They set a "buy" rating and a $81.00 price objective for the company. Stifel Nicolaus cut shares of ChemoCentryx from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. Finally, Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price objective for the company. in a research report on Friday, August 5th.

幾位股票分析師最近發佈了關於CCXI股票的報告。在8月10日星期三的一份研究報告中，股票新聞網站將ChemoCentryx的股票評級從“賣出”上調為“持有”。8月5日，在一份研究報告中，HC Wainwright將ChemoCentryx的股票評級從“買入”下調至“中性”，並將其股票目標價從101.00美元下調至52美元。Canaccel Genuity集團在8月4日星期四的一份研究報告中啟動了對ChemoCentryx股票的報道。他們為該公司設定了“買入”評級和81.00美元的目標價。在8月10日星期三的一份研究報告中，Stifel Nicolaus將ChemoCentryx的股票評級從“買入”下調至“持有”。最後，Canaccel Genuity Group將ChemoCentryx的股票評級從“買入”下調至“持有”，併為該公司設定了52.00美元的目標價。在8月5日星期五的一份研究報告中。

Get
到達
ChemoCentryx
ChemoCentryx
alerts:
警報：

ChemoCentryx Price Performance

ChemoCentryx性價比

CCXI stock opened at $51.37 on Wednesday. The company has a fifty day moving average price of $39.43 and a 200-day moving average price of $28.74. The company has a market capitalization of $3.67 billion, a P/E ratio of -27.18 and a beta of 1.25. ChemoCentryx has a 52-week low of $14.95 and a 52-week high of $51.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.54.

CCXI股價週三開盤報51.37美元。該公司的50日移動均價為39.43美元，200日移動均價為28.74美元。該公司市值為36.7億美元，市盈率為-27.18，貝塔係數為1.25。ChemoCentryx的52周低點為14.95美元，52周高點為51.78美元。該公司的負債權益比率為0.02，速動比率為4.47，流動比率為4.54。

Insider Activity

內幕活動

In other news, CEO Thomas J. Schall sold 130,000 shares of ChemoCentryx stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,393,352 shares in the company, valued at $120,242,004.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Susan M. Kanaya sold 46,298 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.17, for a total transaction of $2,322,770.66. Following the transaction, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,581,373.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas J. Schall sold 130,000 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the transaction, the chief executive officer now directly owns 2,393,352 shares in the company, valued at $120,242,004.48. The disclosure for this sale can be found here. Insiders sold 213,760 shares of company stock worth $10,749,838 over the last three months. 8.30% of the stock is currently owned by insiders.
其他消息方面，首席執行官託馬斯·J·舒爾在一筆日期為8月4日星期四的交易中出售了13萬股ChemoCentryx股票。這些股票以50.24美元的平均價格出售，總成交金額為6,531,200.00美元。交易完成後，首席執行官現在直接擁有該公司2,393,352股，價值120,242,004.48美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下鏈接訪問該文件。在相關新聞中，首席財務官Susan M.Kanaya在一筆日期為8月4日(星期四)的交易中出售了46,298股該公司股票。這些股票的平均價格為50.17美元，總成交額為2,322,770.66美元。交易完成後，首席財務官現在直接持有該公司91,317股股票，價值4,581,373.89美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，可以通過美國證券交易委員會網站訪問該文件。此外，首席執行官託馬斯·J·沙爾在一筆日期為8月4日(星期四)的交易中出售了13萬股公司股票。這些股票以50.24美元的平均價格出售，總成交金額為6,531,200.00美元。交易完成後，這位首席執行官現在直接持有該公司2393,352股股票，價值120,242,004.48美元。此次拍賣的披露信息可在此處找到。過去三個月，內部人士出售了213,760股公司股票，價值10,749,838美元。該公司8.30%的股份目前由內部人士持有。

Institutional Inflows and Outflows

機構資金流入和流出

Large investors have recently made changes to their positions in the company. Engineers Gate Manager LP raised its position in ChemoCentryx by 4.4% in the first quarter. Engineers Gate Manager LP now owns 12,780 shares of the biopharmaceutical company's stock worth $320,000 after acquiring an additional 540 shares during the period. Teacher Retirement System of Texas raised its position in ChemoCentryx by 9.2% in the first quarter. Teacher Retirement System of Texas now owns 9,999 shares of the biopharmaceutical company's stock worth $251,000 after acquiring an additional 841 shares during the period. UBS Asset Management Americas Inc. raised its position in ChemoCentryx by 1.4% in the second quarter. UBS Asset Management Americas Inc. now owns 69,953 shares of the biopharmaceutical company's stock worth $1,733,000 after acquiring an additional 971 shares during the period. Victory Capital Management Inc. raised its position in ChemoCentryx by 7.5% in the second quarter. Victory Capital Management Inc. now owns 14,077 shares of the biopharmaceutical company's stock worth $349,000 after acquiring an additional 981 shares during the period. Finally, Level Four Advisory Services LLC raised its position in ChemoCentryx by 10.9% in the first quarter. Level Four Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company's stock worth $326,000 after acquiring an additional 1,276 shares during the period. 81.09% of the stock is owned by institutional investors.

大型投資者最近對他們在該公司的頭寸進行了調整。工程師門經理LP在第一季度將其在ChemoCentryx的頭寸提高了4.4%。工程師門管理公司現在擁有12,780股這家生物製藥公司的股票，價值32萬美元，在此期間又購買了540股。德克薩斯州教師退休系統第一季度將其在ChemoCentryx的職位提高了9.2%。德克薩斯州教師退休系統在此期間額外購買了841股，現在擁有9999股這家生物製藥公司的股票，價值251,000美元。瑞銀資產管理美洲公司(UBS Asset Management America Inc.)第二季度將其在ChemoCentryx的持倉提高了1.4%。瑞銀資產管理美洲公司(UBS Asset Management America Inc.)目前持有69,953股這家生物製藥公司的股票，價值1,733,000美元，在此期間又購買了971股。勝利資本管理公司在第二季度將其在ChemoCentryx的持倉提高了7.5%。勝利資本管理公司現在擁有14,077股這家生物製藥公司的股票，價值349,000美元，在此期間又購買了981股。最後，Level Four Consulting Services LLC在第一季度將其在ChemoCentryx的頭寸提高了10.9%。Level Four Consulting Services LLC在此期間額外收購了1,276股，現在擁有這家生物製藥公司13,016股股票，價值326,000美元。81.09%的股份由機構投資者持有。

ChemoCentryx Company Profile

ChemoCentryx公司簡介

(Get Rating)

(獲取評級)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

ChemoCentryx，Inc.是一家生物製藥公司，專注於在美國開發和商業化治療炎症性疾病、自身免疫性疾病和癌症的新藥。它提供TAVNEOS(Avacopan)，一種口服的選擇性C5aR抑制劑，用於治療嚴重的抗中性粒細胞胞漿抗體相關小血管炎的成人患者。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
  • These 3 Reports Will Tell Us Much About the Current Economy
  • Is Five Below Trying to Punch Too High?
  • This Is What To Expect From The S&P 500 Now
  • The Two Things You Need To Know About Oracle's FQ1 Report
  • Three Value Stocks For A Volatile Market
  • 免費獲取StockNews.com關於ChemoCentryx(CCXI)的研究報告
  • 這三份報告將告訴我們許多關於當前經濟的情況。
  • 下面的五個是不是打得太高了？
  • 這就是現在對標準普爾500指數的預期
  • 關於甲骨文的FQ1報告，你需要知道的兩件事
  • 波動市場的三隻價值股

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.

接受ChemoCentryx日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ChemoCentryx和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論